^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN SCLC Panel recommends nivolumab as a subsequent therapy option for patients who have relapsed 6 months or less after primary therapy…
